<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00651443</url>
  </required_header>
  <id_info>
    <org_study_id>114-NH-103</org_study_id>
    <nct_id>NCT00651443</nct_id>
  </id_info>
  <brief_title>Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I, Open Label Study to Evaluate the Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the mechanism(s) of action of galiximab in subjects
      with previously untreated follicular NHL.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A company's strategic decision to focus on areas whereit believes it can be competitive and
    decided to exit Oncology
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanism of action of galiximab given as a single agent in previously untreated subjects with follicular NHL.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) Safety and tolerability of Galiximab when administered as a single agent in an extended dosing regimen in previously untreated subjects with follicular NHL. 2) Evaluation of preliminary clinical activity of galiximab.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lymphoma, Non-Hodgkin's</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galiximab</intervention_name>
    <description>Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent (signed and dated).

          -  Age equal or greater than 18 at the time of consent.

          -  Histologically confirmed follicular NHL according to the Revised European American
             Lymphoma (REAL)/ World Health Organization (WHO) classification (from initial
             diagnosis) Grades 1,2, or 3a.

          -  At least 2 malignant lymph nodes of similar size (&gt;1 cm in minimal dimension) and
             location that are readily accessible for excisional biopsy at the time of study entry.

          -  Consent to 1 pretreatment and 1 post-treatment excisional biopsy of accessible tumor.

          -  Acceptable hematologic, hepatic, and renal function parameters.

          -  WHO Performance Status equal or less than 2.

          -  Subjects of reproductive potential must agree to follow accepted birth control
             methods.

        Exclusion Criteria:

          -  Presence of lymphoma in CNS.

          -  Previous systemic anticancer treatment for NHL (including but not limited to
             radiation, myeloablative, or investigational therapy).

          -  Concurrent treatment with systemic steroids within 14 days of Day 1.

          -  Evidence of transformed lymphoma.

          -  Presence of malignancies within 3 years of Study Day 1 (except for adequately treated
             carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of breast, or basal
             or squamous cell skin cancer).

          -  History of HIV infection or AIDS.

          -  Serious nonmalignant disease.

          -  Pregnant.

          -  Inability to comply with study and follow-up procedures.

          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding that contraindicates the use of an investigational drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>January 6, 2011</last_update_submitted>
  <last_update_submitted_qc>January 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Biogen Idec MD</name_title>
    <organization>Biogen Idec</organization>
  </responsible_party>
  <keyword>galiximab</keyword>
  <keyword>Untreated NHL</keyword>
  <keyword>antibody</keyword>
  <keyword>open-label</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

